ESR1 and ESR2 polymorphisms in BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence for early breast cancer.

被引：1
|
作者：
Bouzyk, M.
Gray, K. P.
Regan, M. M.
Pagani, O.
Tang, W.
Kammler, R.
Maibach, R.
Viale, G.
Dell'Orto, P.
Thurlimann, B. J. K.
Hitre, E.
Lyng, M.
Ditzel, H. J.
Neven, P.
MacGrogan, G.
Price, K. N.
Gelber, R. D.
Coates, A. S.
Goldhirsch, A.
Leyland-Jones, B.
机构：
[1] Emory Univ, Sch Med, Atlanta, GA USA
[2] IBCSG Stat Ctr, Boston, MA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Inst Oncol Southern Switzerland, Lugano Viganello, Switzerland
[5] Emory Biomarker Serv Ctr, Atlanta, GA USA
[6] IBCSG Cent Pathol Off, Milan, Italy
[7] IBCSG Coordinating Ctr, Bern, Switzerland
[8] European Inst Oncol, Milan, Italy
[9] Kantonsspital, St Gallen, Switzerland
[10] Natl Inst Oncol, Budapest, Hungary
[11] Univ Southern Denmark, Odense, Denmark
[12] Odense Univ Hosp, DK-5000 Odense, Denmark
[13] UZ Leuven, Louvain, Belgium
[14] Inst Bergonie, Bordeaux, France
[15] Univ Sydney, Sydney, NSW 2006, Australia
[16] Emory Univ, Atlanta, GA 30322 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.1002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1002
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
    Leyland-Jones, Brian
    Gray, Kathryn P.
    Abramovitz, Mark
    Bouzyk, Mark
    Young, Brandon
    Long, Bradley
    Kammler, Roswitha
    Dell'Orto, Patrizia
    Biasi, Maria Olivia
    Thuerlimann, Beat
    Harvey, Vernon
    Neven, Patrick
    Arnould, Laurent
    Maibach, Rudolf
    Price, Karen N.
    Coates, Alan S.
    Goldhirsch, Aron
    Gelber, Richard D.
    Pagani, Olivia
    Viale, Giuseppe
    Rae, James M.
    Regan, Meredith M.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 154 (03) : 543 - 555
  • [2] ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
    Brian Leyland-Jones
    Kathryn P. Gray
    Mark Abramovitz
    Mark Bouzyk
    Brandon Young
    Bradley Long
    Roswitha Kammler
    Patrizia Dell’Orto
    Maria Olivia Biasi
    Beat Thürlimann
    Vernon Harvey
    Patrick Neven
    Laurent Arnould
    Rudolf Maibach
    Karen N. Price
    Alan S. Coates
    Aron Goldhirsch
    Richard D. Gelber
    Olivia Pagani
    Giuseppe Viale
    James M. Rae
    Meredith M. Regan
    Breast Cancer Research and Treatment, 2015, 154 : 543 - 555
  • [3] Bone mineral density (BMD) in participants (pts) of trial BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence
    De Censi, A.
    Sun, Z.
    Thurlimann, B. J. K.
    McIntosh, C.
    Guerrieri-Gonzaga, A.
    Monnier, A.
    Tondini, C.
    Campone, M.
    Mauriac, L.
    Zaman, K.
    Schoenberger, A.
    Price, K. N.
    Gelber, R. D.
    Goldhirsch, A.
    Coates, A. S.
    Aebi, S. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms
    McIntyre, Matthew H.
    Kantoff, Philip W.
    Stampfer, Meir J.
    Mucci, Lorelei A.
    Parslow, Diane
    Li, Haojie
    Gaziano, J. Michael
    Abe, Miyako
    Ma, Jing
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (11) : 2233 - 2236
  • [5] Association Between ESR1 and ESR2 Polymorphisms and Risk of Colorectal Cancer in Chinese Han Population
    Wu, H. L.
    Yuan, X. L.
    Xiong, H. H.
    Hu, G. Y.
    Cai, J.
    Xu, H.
    Hu, J.
    Chen, J. G.
    Chen, X. P.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S399 - S399
  • [6] Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial
    Phillips, Kelly-Anne
    Ribi, Karin
    Sun, Zhuoxin
    Stephens, Alisa
    Thompson, Alastair
    Harvey, Vernon
    Thuerlimann, Beat
    Cardoso, Fatima
    Pagani, Olivia
    Coates, Alan S.
    Goldhirsch, Aron
    Price, Karen N.
    Gelber, Richard D.
    Bernhard, Juerg
    BREAST, 2010, 19 (05): : 388 - 395
  • [7] Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
    DeCensi, Andrea
    Sun, Zhuoxin
    Guerrieri-Gonzaga, Aliana
    Thuerlimann, Beat
    McIntosh, Christina
    Tondini, Carlo
    Monnier, Alain
    Campone, Mario
    Debled, Marc
    Schoenenberger, Astrid
    Zaman, Khalil
    Johansson, Harriet
    Price, Karen N.
    Gelber, Richard D.
    Goldhirsch, Aron
    Coates, Alan S.
    Aebi, Stefan
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 144 (02) : 321 - 329
  • [8] 12 years' median follow up (MFU) of BIG 1-98: Adjuvant letrozole, tamoxifen and their sequence for postmenopausal women with endocrine responsive early breast cancer
    Thuerlimann, B.
    Giobbie-Hurder, A.
    Colleoni, M.
    Jensen, M-B
    Ejlertsen, B.
    de Azambuja, E.
    Neven, P.
    Lang, I.
    Gladieff, L.
    Bonnefoi, H.
    Harvey, V. J.
    Spazzapan, S.
    Tondini, C.
    Price, K.
    Piccart-Gebhart, M.
    Regan, M. M.
    Gelber, R. D.
    Coates, A. S.
    Goldhirsch, A.
    CANCER RESEARCH, 2017, 77
  • [9] Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
    Andrea DeCensi
    Zhuoxin Sun
    Aliana Guerrieri-Gonzaga
    Beat Thürlimann
    Christina McIntosh
    Carlo Tondini
    Alain Monnier
    Mario Campone
    Marc Debled
    Astrid Schönenberger
    Khalil Zaman
    Harriet Johansson
    Karen N. Price
    Richard D. Gelber
    Aron Goldhirsch
    Alan S. Coates
    Stefan Aebi
    Breast Cancer Research and Treatment, 2014, 144 : 321 - 329
  • [10] Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)
    Zaman, K.
    Thuerlimann, B.
    Huober, J.
    Schoenenberger, A.
    Pagani, O.
    Luethi, J.
    Simcock, M.
    Giobbie-Hurder, A.
    Berthod, G.
    Genton, C.
    Brauchli, P.
    Aebi, S.
    ANNALS OF ONCOLOGY, 2012, 23 (06) : 1474 - +
12345